Indicated for: Helicobacter pylori infection; peptic ulcer
Route of administration: oral
Substance: bismuth subcitrate (antacid)
ATC: A02BX05 (Alimentary tract and metabolism | Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) | Other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord))
Bismuth subcitrate is primarily used for the treatment of gastrointestinal conditions such as gastric and duodenal ulcers, gastritis, and infections caused by Helicobacter pylori. This compound has gastroprotective, antimicrobial, and anti-inflammatory properties and is often included in combination therapies for H. pylori eradication.
Bismuth subcitrate works by forming a protective layer over the gastric mucosa, shielding it from the effects of gastric acid and digestive enzymes. It also has a direct antimicrobial effect against H. pylori, helping to reduce inflammation and promote ulcer healing. This medication is commonly used in combination with antibiotics and proton pump inhibitors (PPIs) in eradication regimens.
While bismuth subcitrate is effective, its use may cause some side effects, such as nausea, constipation, or black stools (due to the bismuth content). These effects are usually temporary and harmless. However, prolonged use or high doses can lead to bismuth accumulation in the body, which may cause toxicity (bismuth encephalopathy), although this is rare.
This medication should be used as directed by a doctor, and patients should adhere to the recommended dosage. It is important to avoid concurrent use with other bismuth-containing medications or antacids, as these may reduce the effectiveness of the treatment. If severe side effects or persistent symptoms occur, medical advice should be sought.